Breast cancer is the second leading cause of death for women worldwide. The
heterogeneity of this disease presents a big challenge in its therapeutic management …

HER2 status in breast cancer is assessed to select patients eligible for targeted therapy with
anti-HER2 therapies. According to the American Society of Clinical Oncology (ASCO) and …

The approach of peptide-based anticancer vaccination has proven the ability to induce
cancer-specific immune responses in multiple studies for various cancer entities. However …

Breast cancer has become the most commonly diagnosed cancer globally. The relapse and
metastasis of breast cancer remain a great challenge despite advances in chemotherapy …

The ability to exploit the immune system as a weapon against cancer has revolutionised the
treatment of cancer patients, especially through immune checkpoint inhibitors (ICIs) …

Triple-negative breast cancer (TNBC) is the subtype of breast cancer with the poorest
outcomes, and is associated with a high risk of relapse and metastasis. The treatment …

Simple Summary Human epidermal growth factor receptor 2 (HER2) positive breast cancer
is a heterogeneous disease. Among different therapeutic approaches, immunotherapies …

Breast cancer is the leading cause of death in women from 20 to 59 years old. The
conventional treatment includes surgery, chemotherapy, hormonal therapy, and …

Triple-negative breast cancers (TNBCs) are aggressive tumors that are more common in
young women, African American populations, and those with hereditary mutations. These …

Abstract Background The E75 and GP2 vaccines are the few therapeutic vaccines targeting
HER2 currently under clinical research for patients with breast cancer. Methods Databases …